Reviewing Prelude Therapeutics (NASDAQ:PRLD) and Keros Therapeutics (NASDAQ:KROS)

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) and Keros Therapeutics (NASDAQ:KROS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Prelude Therapeutics and Keros Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prelude Therapeutics N/A -60.91% -35.51%
Keros Therapeutics -256.60% -21.85% -19.83%

Valuation and Earnings

This table compares Prelude Therapeutics and Keros Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prelude Therapeutics $12.14 million 21.23 -$99.50 million ($0.59) -5.47
Keros Therapeutics $244.06 million 0.89 $87.01 million ($2.82) -3.91

Keros Therapeutics has higher revenue and earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Prelude Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Prelude Therapeutics and Keros Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prelude Therapeutics 1 1 5 0 2.57
Keros Therapeutics 1 2 3 1 2.57

Prelude Therapeutics presently has a consensus price target of $8.75, indicating a potential upside of 170.90%. Keros Therapeutics has a consensus price target of $20.00, indicating a potential upside of 81.16%. Given Prelude Therapeutics’ higher probable upside, research analysts clearly believe Prelude Therapeutics is more favorable than Keros Therapeutics.

Insider & Institutional Ownership

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Prelude Therapeutics beats Keros Therapeutics on 8 of the 13 factors compared between the two stocks.

About Prelude Therapeutics

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

About Keros Therapeutics

(Get Free Report)

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function. The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions.

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.